

Supplementary Figure 1. (A) Representative flow cytometry plots of the gating strategy for CECs in a female mouse. (B) Cumulative data of the body weight per gram (gr) of BALB/c male versus female mice. (C) Cumulative data of the spleen weight in BALB/c male and female mice.
(D) Cumulative data of the body weight per gram (gr) of C57BL/6 male versus female mice.
(E) Cumulative data of the spleen weight in C57BL/6 male and female mice. (F) Representative plots and cumulative data of CD45+CECs in newborn mice. (G) Cumulative data of VISTA expression on CECs in male versus female BALB/c, and (H) C57BL/6 mice. (I) Cumulative data of PDL-1 expression in CECs of male versus female BALB/c, and (J) C57BL/6 mice. (K) Cumulative data comparing PDL-1 expression in male/female BALB/c with C57BL/6 mice. (L) Cumulative data comparing VISTA expression in male/female BALB/c with C57BL/6 mice. Each dote represents data from one individual animal and obtained from multiple independent experiments.



**Supplementary Figure 2**. (**A**) Representative histogram of ROS expression in a male versus female C57BL/6 or BALB/c mouse. (**B**) Cumulative data of the expression of ROS as measured by the mean fluorescence intensity (MFI) in CD45+CECs in female C57BL/c versus BALB/c mice. (**C**) Representative flow cytometry plots of gating strategy for the fetal liver CECs and the expression of arginase II (Arg II) in CD71<sup>high</sup> and CD71<sup>low</sup> CECs. (**D**) Cumulative data of arginase I (Arg I) expression in CD45+CECs in male and female BALB/c mice. (**E**) Cumulative data of arginase I (Arg I) expression in CD45+and CD45+CECs in male and female BALB/c mice. (**E**) Cumulative data of arginase I (Arg I) expression in CD45- and CD45+CECs in male and female C57BL/c compred to their counterparts in female BALB/c mice. (**G**) Representative histogram of enriched CECs shown as TER119+ cells/pre and post-enrichment (purity of 96.8%).



**Supplementary Figure 3.** (A) Cumulative data of CD4+ T cell proliferation, and (B) CD8+ T cells proliferation as measured by CFSE dilution in the absence or presence of CECs from female or male mice at indicated ratio of (1:1) following stimulation with anti-CD3/CD28 antibodies for 3 days. (C) Representative histogram of arginase II (Arg II) expression in CECs from anemic mice compared to mature red blood cells (RBCs). (D) Percentages of CD4+ and CD8+ T cells in the spleen of female and male C57BL/6 mice. (E) Representative flow cytometry plots, and (F) cumulative data of % CECs in the spleen of male mice following administration of the anti-TER119 antibody compared to controls (Isotype antibody-treated). (G) (H) Cumulative data showing absolute count of CD11b-CD169+F4/80+ cells in the spleen of BALB/c, and (I) C57BL/c female and male mice. (J) The gating strategy for CECs in a female human. (K) Representative histogram of enriched CECs shown as CD235a+ cells/pre and post-enrichment obtained from a human female. Each dote represents data from an individual animal and obtained from at least from two independent experiments.